Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia

Fig. 1

Hemodynamic studies and immunohistochemical evaluation of PAH models with and without silibinin. a Silibinin decreased RVSP and Fulton index in the Sil-1w group compared to the PAH-1w group. b Silibinin also decreased RVSP and Fulton index in the Sil-2w group compared to the PAH-2w. c Silibinin did not decrease RVSP and Fulton index during the 3-week experiment. d SMA staining revealed thinner media smooth muscle layer in the Sil-2w group compared to that in the PAH-2w group, but this was no longer found after 1 or 3 weeks. e PCNA staining revealed less proliferation in PAs in the Sil-2w group compared to PAH-2w, but no change was observed when compared to the 1- and 3-week treatment periods. f-h % MT and VOS were calculated at 1 week (f), 2 weeks (g), and 3 weeks (h) of treatment. Significant differences were found at the 2-week time point only (g); *p < 0.05 and **p < 0.01. Treatment groups consisted of eight rats each in the PAH-1w, PAH-2w, Sil-1w, and Sil-2w groups and four rats each in the PAH-3w and Sil-3w groups

Back to article page